Vitreoretinal Disorder Market Report 2026

The vitreoretinal disorder market size has grown strongly in recent years. It will grow from $4.63 billion in 2025 to $4.99 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increasing prevalence of diabetic eye diseases, wider availability of optical coherence tomography, growth in ophthalmic surgical procedures, expansion of specialty eye clinics, improved diagnostic accuracy.

The vitreoretinal disorder market size is expected to see strong growth in the next few years. It will grow to $6.71 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing demand for personalized retinal treatments, rising investments in ophthalmic innovation, expansion of minimally invasive surgical techniques, growing use of ai-driven diagnostics, increasing focus on vision preservation therapies. Major trends in the forecast period include increasing adoption of advanced retinal imaging techniques, rising use of minimally invasive vitreoretinal surgery, growing integration of AI-based diagnostic tools, expansion of targeted retinal therapies, enhanced focus on early disease detection.

The growing incidence of diabetic retinopathy is expected to drive the growth of the vitreoretinal disorder market going forward. Diabetic retinopathy is an eye condition caused by damage to the blood vessels in the retina due to high blood sugar levels in people with diabetes. Its incidence is rising alongside the increasing prevalence of diabetes, which is fueled by sedentary lifestyles and poor blood sugar control, leading to damage of retinal blood vessels. Management of vitreoretinal disorders plays a key role in treating diabetic retinopathy by addressing complications such as vitreous hemorrhage and tractional retinal detachment, thereby preserving vision and preventing further retinal damage. For instance, in October 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2022-23, 1.8% of screened First Nations people in Australia received treatment for diabetic retinopathy, with a lower age-standardized treatment rate (1.3%) than non-Indigenous Australians (1.5%). Therefore, the growing incidence of diabetic retinopathy is driving the growth of the vitreoretinal disorder market.

Major companies operating in the vitreoretinal disorder market are focusing on innovative solutions such as continuous delivery drug systems to reduce injection frequency and improve patient outcomes. Continuous delivery drug systems are medical platforms that provide a sustained, controlled release of medication directly to the eye, helping reduce the need for frequent injections, maintain consistent therapeutic levels, and improve patient adherence and visual outcomes. For instance, in February 2025, Roche, a Switzerland-based global pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Susvimo (ranibizumab injection) 100 mg/mL, a Port Delivery System for diabetic macular edema (DME). Susvimo delivers ranibizumab continuously via a refillable implant, allowing patients to maintain vision with as few as two treatments per year, compared with monthly eye injections. The system was evaluated in the Phase III Pagoda study, showing sustained improvements in visual acuity and safety consistent with prior approvals for neovascular age-related macular degeneration (nAMD). Susvimo’s platform reduces treatment burden, enhances patient convenience, and addresses the growing prevalence of DME worldwide.

In July 2024, Merck & Co. Inc., a US-based pharmaceutical company, acquired Eyebiotech Limited (EyeBio) for $3 billion. Through this acquisition, Merck aims to strengthen its eye disease treatment portfolio, gaining Restoret (EYE103), a drug for diabetic macular edema (DME) and wet age-related macular degeneration (nAMD). Eyebiotech Limited is a UK-based clinical-stage ophthalmology biotechnology company focused on developing treatments for retinal diseases, including vitreoretinal conditions.

Major companies operating in the vitreoretinal disorder market are F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Regeneron Pharmaceuticals Inc., Alcon Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd., Topcon Corporation, Carl Zeiss Meditec AG, Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Kodiak Sciences Inc., Clearside Biomedical, Apellis Pharmaceuticals Inc., Genentech Inc., Oxurion NV, Adverum Biotechnologies Inc., Opthea Limited, Graybug Vision Inc., Kiora Pharmaceuticals Inc., Allegro Ophthalmics Inc., Lineage Cell Therapeutics Inc., Ocugen Inc.

North America was the largest region in the vitreoretinal disorder market in 2025. The regions covered in the vitreoretinal disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vitreoretinal disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the vitreoretinal disorder market by increasing costs of imported surgical instruments, diagnostic imaging systems, lasers, and pharmaceutical agents used in retinal treatments. Ophthalmology centers in North America and Europe are most affected due to reliance on advanced imported equipment, while Asia-Pacific faces cost pressure in device manufacturing and exports. These tariffs are raising procedure costs and delaying technology upgrades. However, they are also encouraging regional manufacturing of ophthalmic devices, localized service networks, and long-term investment in domestic retinal care technologies.

The vitreoretinal disorder market research report is one of a series of new reports that provides vitreoretinal disorder market statistics, including vitreoretinal disorder industry global market size, regional shares, competitors with a vitreoretinal disorder market share, detailed vitreoretinal disorder market segments, market trends and opportunities, and any further data you may need to thrive in the vitreoretinal disorder industry. This vitreoretinal disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vitreoretinal disorder refers to a group of eye conditions that impact the retina and the vitreous humor, which are essential for maintaining the eye’s shape and visual clarity. These disorders can progressively impair vision and often require advanced diagnostic techniques and specialized medical or surgical treatments for effective management.

The main types of vitreoretinal disorders include retinal tears, retinal detachment, diabetic retinopathy, macular degeneration, macular holes, and others. A retinal tear is a small break or rip in the retina, the light-sensitive tissue at the back of the eye. Diagnostic methods include digital fluorescein angiography, optical coherence tomography, Heidelberg retinal tomography, indocyanine green angiography, and others, with treatment options such as surgery, medication, and more. These treatments are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, serving end users such as hospitals, home care providers, specialty clinics, and others.

The vitreoretinal disorder market includes revenues earned by entities by providing services such as diagnostic services, intravitreal injection therapies, imaging services, teleophthalmology consultations, postoperative care, and retinal rehabilitation services. The vitreoretinal disorder market also includes sales of fundus cameras, injections, and steroid implants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.